Drug Profile
MK 0812
Alternative Names: MK-0812Latest Information Update: 22 Mar 2010
Price :
$50
*
At a glance
- Originator Merck & Co
- Class Naphthyridines; Small molecules
- Mechanism of Action CCR2 receptor antagonists
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Discontinued Atherosclerosis; Multiple sclerosis; Rheumatoid arthritis
Most Recent Events
- 17 Apr 2007 Preclinical trials in Atherosclerosis in USA (unspecified route)